Influenza vaccine: an effective preventive vaccine for developing countries

Area of Science:

• Virology
• Public Health
• Immunology

Background:

• Influenza viruses A, B, and C cause illness in humans, birds, and animals, with Type A leading to moderate to severe illness across all age groups.
• Influenza A subtypes A(H1N1) and A(H3N2) are currently circulating, posing a significant public health concern due to frequent mutations (antigenic drift and shift).
• The 2009 novel Influenza A (H1N1) pandemic, an example of antigenic shift, resulted in approximately 18,000 global deaths by August 2010, with highest illness and hospitalization rates in children and young adults.

Purpose of the Study:

• To provide an overview of influenza viruses, their impact on public health, and the role of vaccination in prevention.
• To discuss the characteristics of influenza virus mutations, including antigenic drift and shift.
• To highlight the significance of Trivalent Inactivated Vaccines (TIV) in mitigating severe influenza outcomes.

Main Methods:

• Review of existing literature on influenza virus types, subtypes, and their epidemiological impact.
• Analysis of mutation patterns, including antigenic drift and shift, with a focus on Influenza A.
• Description of Trivalent Inactivated Vaccines (TIV) formulations and their production methods.

Main Results:

• Influenza A, B, and C viruses cause disease, with Type A being more severe and prevalent.
• Antigenic drift and shift are key characteristics of influenza viruses, enabling rapid global spread and necessitating vaccine updates.
• Vaccination, specifically TIVs (split-product or subunit surface-antigen), is the most effective preventive measure against severe influenza illness and complications.

Conclusions:

• Influenza poses a continuous threat to global health, necessitating ongoing surveillance and vaccination efforts.
• Understanding influenza virus evolution, particularly antigenic shifts, is crucial for developing effective vaccines.
• Trivalent Inactivated Vaccines (TIV) are vital tools for preventing severe influenza disease, especially in high-risk populations.